{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alternating+stimulation&page=4", "query": { "intervention": "Alternating stimulation", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 189, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alternating+stimulation&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alternating+stimulation&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T02:32:09.667Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07093736", "title": "A Study Comparing Immediate Treatment to Deferred Treatment With the Fisher Wallace (FW) Stimulator FW-200 Device for the Treatment of Self-reported Anxiety in First Responders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety" ], "interventions": [ { "name": "FW-200", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Fisher Wallace Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2021-07-06", "completion_date": "2023-05-11", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Seattle, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07093736" }, { "nct_id": "NCT06023641", "title": "Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rhabdomyosarcoma" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Dactinomycin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Proton beam radiation or external beam radiation or brachytherapy", "type": "PROCEDURE" }, { "name": "Liposomal irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Filgrastim, peg-filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 135, "start_date": "2024-03-13", "completion_date": "2037-10", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 3, "location_summary": "Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06023641" }, { "nct_id": "NCT05626426", "title": "Electrical Stimulation for the Treatment of Optic Neuropathies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glaucoma", "Glaucoma, Open-Angle", "Optic Nerve Diseases" ], "interventions": [ { "name": "Repetitive, Transorbital Alternating Current Stimulation (rtACS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-02-27", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05626426" }, { "nct_id": "NCT00521014", "title": "GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 14, "start_date": "2007-10", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-12-22", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00521014" }, { "nct_id": "NCT07224334", "title": "Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes (DM)" ], "interventions": [ { "name": "Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dextrose 20% solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David D'Alessio, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2025-12-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224334" }, { "nct_id": "NCT04591288", "title": "FES to Improve Gait in CP", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cerebral Palsy", "Spastic Diplegia Cerebral Palsy", "Gait" ], "interventions": [ { "name": "Functional Electrical Stimulation protocol", "type": "OTHER" }, { "name": "Treadmill only protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Shriners Hospitals for Children", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 2, "start_date": "2019-10-24", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 2, "location_summary": "Newark, Delaware • Philadelphia, Pennsylvania", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04591288" }, { "nct_id": "NCT05022147", "title": "Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson Disease", "Gait Disorders, Neurologic", "Disease Progression", "Subthalamic Nucleus", "Accidental Fall", "Deep Brain Stimulation" ], "interventions": [ { "name": "High-Frequency-Only Stimulation", "type": "DEVICE" }, { "name": "Low-Frequency-Only Stimulation", "type": "DEVICE" }, { "name": "Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation", "type": "DEVICE" }, { "name": "Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation", "type": "DEVICE" }, { "name": "Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation", "type": "DEVICE" }, { "name": "Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation", "type": "DEVICE" }, { "name": "OFF Dopaminergic Medication", "type": "DRUG" }, { "name": "ON Dopaminergic Medication", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "James Liao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 12, "start_date": "2021-10-04", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05022147" }, { "nct_id": "NCT06891638", "title": "Enhancing Reading Recovery in Aphasia With tDCS and Phonomotor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke", "Aphasia" ], "interventions": [ { "name": "Schedule of tDCS administration", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Kessler Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2025-05-12", "completion_date": "2026-02-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 2, "location_summary": "West Orange, New Jersey • Milwaukee, Wisconsin", "locations": [ { "city": "West Orange", "state": "New Jersey" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891638" }, { "nct_id": "NCT07675408", "title": "Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Parkinson's Disease With Freezing of Gait" ], "interventions": [ { "name": "CueStim", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Fortis Medical Devices Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 60, "start_date": "2026-10", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 6, "location_summary": "Boca Raton, Florida • Daytona Beach, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675408" }, { "nct_id": "NCT01909011", "title": "A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bi-polar II Disorder" ], "interventions": [ { "name": "Active CES", "type": "DEVICE" }, { "name": "Sham CES", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 16, "start_date": "2013-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-10-27T02:32:09.667Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909011" } ] }